This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pérez-Vázquez, M.
Right arrow Articles by Campos, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pérez-Vázquez, M.
Right arrow Articles by Campos, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2007, p. 1566-1569, Vol. 51, No. 4
0066-4804/07/$08.00+0     doi:10.1128/AAC.01437-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Fluoroquinolone Resistance in Haemophilus influenzae Is Associated with Hypermutability{triangledown}

María Pérez-Vázquez,1 Federico Román,1 Silvia García-Cobos,1 and José Campos1,2*

Antibiotic Laboratory, Bacteriology Service, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain,1 Consejo Superior de Investigaciones Científicas, Madrid, Spain2

Received 17 November 2006/ Returned for modification 22 December 2006/ Accepted 26 January 2007


arrow
ABSTRACT
 
Forty-three percent (12/28) of ciprofloxacin (CIP)-nonsusceptible respiratory isolates of Haemophilus influenzae were hypermutable, compared with 8.5% (3/35) in the CIP-susceptible control group (P = 0.002). CIP-nonsusceptible mutants were obtained with hypermutable strains only; these mutants developed three resistance mechanisms in a step-by-step process: target modifications, loss of a porin protein, and increased efflux.


arrow
TEXT
 
Fluoroquinolone-resistant Haemophilus influenzae isolates have been described in several countries (4, 5, 8, 17, 19). In general, hypermutable isolates contribute to the emergence of antibiotic resistance (3, 9). Fluoroquinolone resistance in Staphylococcus aureus is related to hypermutability (23). We and other authors have reported a high prevalence of hypermutable H. influenzae isolates causing respiratory infections (22, 24). We also noticed a high rate of fluoroquinolone resistance in these isolates (22) and reported a therapeutic failure in a community-acquired pneumonia case due to levofloxacin-resistant H. influenzae (2).

The main mechanism of fluoroquinolone resistance in H. influenzae is amino acid changes in the quinolone resistance-determining region (QRDR) of the topoisomerase II and I genes (5, 8, 9). Although not reported in H. influenzae, mutations resulting in overexpression of efflux pumps and permeability defects can also affect quinolone susceptibility (12).

In this study, we investigated the hypothesis that ciprofloxacin (CIP) resistance in H. influenzae occurs mainly in hypermutable clinical isolates. To test this hypothesis, first we made an observational study, and after that, we subjected CIP-susceptible hypermutable isolates to selective pressure with CIP. We also characterized other mechanisms of resistance in highly fluoroquinolone-resistant isogenic mutants as overexpression of efflux pumps and permeability defects.

The CIP reduced-susceptibility study group included 28 clinical isolates (3 from the United States [1] and 25 from Spain) chosen because they had amino acid changes in GyrA of the QRDR (21) and corresponding MICs for CIP of 0.12 to 32 µg/ml. The CIP-susceptible control group contained 35 clinical strains without amino acid changes and corresponding MICs for CIP of <0.12 µg/ml. All strains were noncapsulated and were isolated from respiratory specimens of adult patients with chronic respiratory infections (19, 21).

The study of mutation frequencies in response to rifampin was done in triplicate as described previously (22). Isolates were considered hypermutable if their mutation frequency was 10–7 CFU/ml or higher (22). Forty-three percent of the strains (12/28) in the study group were hypermutable, compared to 8.5% (3/35) in the control group (odds ratio, 8; P, 0.0024). The average mutation frequencies in the two groups (4 x 10–6 CFU/ml for the study group and 7 x 10–8 CFU/ml for the control group) differed significantly (P, 0.017; Mann-Whitney U test). The mutation frequency distributions are shown in Fig. 1. A positive correlation was found between mutation frequency and the MIC for CIP (Pearson coefficient = 0.34; P = 0.006).


Figure 1
View larger version (8K):
[in this window]
[in a new window]

  		FIG. 1. Distribution of H. influenzae strains according to their mutation frequency in response to rifampin and according to the presence of amino acid changes in the quinolone resistance-determining region of GyrA. The control group comprises strains with no amino acid changes in the quinolone resistance-determining region of GyrA and MICs for CIP of <0.12 µg/ml. The study group comprises strains with amino acid changes in the quinolone resistance-determining region of GyrA and MICs for CIP of 0.12 µg/ml to 32 µg/ml. Horizontal bars represent the average mutation frequency of the study group (4 x 10–6 CFU/ml) and the control group (7 x 10–8 CFU/ml) (P = 0.017; Mann-Whitney U test).

We further subjected 12 susceptible clinical isolates of H. influenzae to in vitro selective pressure with CIP in a step-by-step procedure in Haemophilus test medium plates containing 0.1, 0.2, 0.5, 1, 2, and 10 µg/ml CIP. Six isolates were nonhypermutable, and the other six were hypermutable; all had MICs for CIP of <0.12 µg/ml and were without amino acid substitutions in GyrA or ParC. Three of the hypermutable fluoroquinolone-susceptible strains came from a previous study (22).

We obtained isogenic in vitro nonsusceptible mutants from only four hypermutable isolates (Table 1). Using overlapping primer sets (Table 2), we sequenced the mutS and mutL genes of these four hypermutable clinical isolates (named A to D), and representative CIP-nonsusceptible isogenic mutants identified as A1 to A4 (derived from strain A), B1 and B2 (from strain B), C1 to C3 (from strain C) and D1 to D4 (from strain D) (Table 1). As a control, we used a nonhypermutable and fluoroquinolone-susceptible clinical isolate. All sequences were compared with that of H. influenzae Rd KW20 (7). No amplifications were obtained with primers for the first mutS DNA fragment, possibly due to a deletion in the gene. No changes were identified in the mutS sequence, but all strains presented one common mutation (Asn589Asp) in mutL that did not appear in the nonhypermutable control strain.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Quinolone susceptibility, amino acid changes in GyrA and ParC quinolone resistance-determining regions, and changes detected in AcrR from Haemophilus influenzae isolatesa


View this table:
[in this window]
[in a new window]

  		TABLE 2. Characteristics of specific primers used for the sequencing of mutS and mutL in the present study

The DNA sequences of gyrA, gyrB, parC, and parE in the QRDR were determined in strains A, B, C, and D and in all isogenic CIP-resistant mutants, as described previously (21). CIP-nonsusceptible mutants also presented decreased susceptibility to other quinolones (Table 1). No mutations of GyrA or ParC in the QRDR were detected in wild isolate A, B, C, or D, but they were present in all mutants analyzed. All of these changes are involved in fluoroquinolone resistance (20, 25). No changes in GyrB and ParE of the QRDR were observed.

There was incomplete agreement between the level of resistance to fluoroquinolones and the number of amino acid changes identified. For instance, the four mutants derived from strain A had the same amino acid substitution pattern in GyrA and ParC although their MICs varied from 0.25 to 4 µg/ml (Table 1), suggesting that additional resistance mechanisms such as permeability and/or active efflux may be present.

Profiles of outer membrane proteins were obtained as described previously (22) for wild strains A and D and their isogenic mutants. We observed the disappearance of the major ~40-kDa P2 porin band (Fig. 2, lanes 4, 5, and 9), which has been shown to present a homology of 25% in the primary amino acid sequence with the OmpF porin of Escherichia coli (11), which is involved in CIP resistance (6).


Figure 2
View larger version (59K):
[in this window]
[in a new window]

  		FIG. 2. Profile of outer membrane proteins in the H. influenzae wild strains A (lane 1) and D (lane 6) and their in vitro mutants A1, A2, A3, and A4 (lanes 2 to 5) and D1, D2, and D4 (lanes 7 to 9). Outer membrane protein porin P2 is indicated. KD and M, molecular mass markers in kDa.

A potential active efflux mechanism of resistance was determined in triplicate by spectrophotometrically measuring the accumulation of CIP and norfloxacin in strains A and A4, C and C3, and D and D4. Bacterial cells were incubated with and without cyanide 3-chlorophenyl (CCCP; 0.1 mM) and Phe-Arg-ß-naphthylamide (MC-207,110 compound; 0.1 mM) as efflux pump inhibitors (14, 15). By definition, a strain expressed energy-dependent accumulation when the pump inhibitor enhanced the basal level of accumulation by at least 50% (16).

We detected a significant increase in the accumulation of fluoroquinolones for the MC-207,110 compound, which was more evident for norfloxacin than for CIP. Norfloxacin accumulation increased by 2,126% (21 times) in the mutant strain C3 compared with strain C, and 140% (1.4 times) in the isogenic mutant A4 with respect to strain A. In the D/D4 strains, the increase exceeded 50% for D4 but an increase was also seen for the wild strain D (Fig. 3).


Figure 3
View larger version (5K):
[in this window]
[in a new window]

  		FIG. 3. Accumulation of norfloxacin in three pairs of isogenic strains in the absence (basal) and presence (0.1 mM) of MC-207,110. Vertical lines separate wild strains (A, C, and D) from their in vitro mutants (A4, C3, and D4). The data shown are the averages ± standard deviations of triplicate experiments. *, increase over basal accumulation of 2,126% (21 times); **, increase over basal accumulation of 140% (1.4 times).

Since an efflux mechanism appeared to be involved, we sequenced the acrR gene, which codes for a repressor of the AcrAB-ToldC homolog efflux pump in H. influenzae, in the four wild strains and in the CIP-nonsusceptible isogenic strains (13). However, the mutants and wild strains had identical acrR sequences (Table 1).

In this study, we have shown that hypermutability is a risk condition for the development of fluoroquinolone resistance in H. influenzae. Since hypermutable isolates are particularly frequent in chronic respiratory infections (22, 24), precautions are advised when treating these patients with fluoroquinolones. This study confirms that target modification is the first and most important mechanism of fluoroquinolone resistance in H. influenzae; however, two new associated mechanisms, increased efflux and porin loss, also appear to be important in explaining increased levels of resistance to fluoroquinolones in this pathogen.


arrow
ACKNOWLEDGMENTS
 
We thank the Biopolymers and Spongiform Encephalopathy units of the ISCIII.

S.G. is the recipient of a fellowship of the ISCIII (reference 05/0033). This work was supported by research grants from the ISCIII, REIPI Network (reference RD 06/0008/0023), the Network of Excellence GRACE (PL 518226), and "Fondó de Investigaciones cientificas" (FIS, PI 04/0899).


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain. Phone: 34 918223650. Fax: 34 915097966. E-mail: jcampos{at}isciii.es Back

{triangledown} Published ahead of print on 5 February 2007. Back


arrow
REFERENCES
 
    1
  1. Barriere, S. L., and J. Hindler. 1993. Ciprofloxacin resistant Haemophilus influenzae in a patient with chronic lung disease. Ann. Pharmacother. 27:309-310.[Abstract]
    2. 2
  2. Bastida, T., M. Perez-Vazquez, J. Campos, M. C. Cortes-Lletget, F. Roman, F. Tubau, A. G. de la Campa, and C. Alonso-Tarres. 2003. Levofloxacin treatment failure in Haemophilus influenzae pneumonia. Emerg. Infect. Dis. 9:1475-1478.[Medline]
    3. 3
  3. Blázquez, J. 2003. Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin. Infect. Dis. 37:1201-1209.[CrossRef][Medline]
    4. 4
  4. Bootsma, H. G., A. Troelstra, A. V. Veen-Rutgers, F. R Mooi, A. J. de Neeling, and B. P. Overbeek. 1997. Isolation and characterization of a ciprofloxacin-resistant isolate of Haemophilus influenzae from The Netherlands. J. Antimicrob. Chemother. 39:292-293.[Free Full Text]
    5. 5
  5. Campos, J., F. Román, M. Georgiou, C. García, R. Gómez-Lus, R. Cantón, H. Escobar, and F. Baquero. 1996. Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. J. Infect. Dis. 174:1345-1347.[Medline]
    6. 6
  6. Cohen, S. P., L. M. McMurry, D. C. Hooper, J. S. Wolfson, and S. B. Levy. 1989. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob. Agents Chemother. 33:1318-1325.[Abstract/Free Full Text]
    7. 7
  7. Fleischmann, R. D., M. D. Adams, O. White, R. A. Clayton, E. F. Kirkness, A. R. Kerlavage, C. J. Bult, J. F. Tomb, B. A. Dougherty, J. M. Merrick, et al. 1995. Whole-genome random sequencing and assembly of H. influenzae Rd. Science 269:449-604.
    8. 8
  8. Georgiou, M., R. Muñoz, F. Román, R. Cantón, R. Gómez-Lus, J. Campos, and A. G. De La Campa. 1996. Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. Antimicrob. Agents Chemother. 40:1741-1744.[Abstract]
    9. 9
  9. Giraud, A., I. Mastic, M. Radman, M. Fons, and F. Taddei. 2002. Mutator bacteria as a risk factor in treatment of infectious diseases. Antimicrob. Agents Chemother. 46:863-865.[Abstract/Free Full Text]
    10. 10
  10. Reference deleted.
    11. 11
  11. Hansen, E. J., C. Hasemann, A. Clausell, J. D. Capra, K. Orth, C. R. Moomaw, C. A. Slaughter, J. L. Latimer, and E. Miller. 1989. Primary structure of the porin protein of Haemophilus influenzae type b determined by nucleotide sequence analysis. Infect. Immun. 57:1100-1107.[Abstract/Free Full Text]
    12. 12
  12. Hooper, D. C. 2005. Efflux pumps and nosocomial antibiotic resistance: a primer for hospital epidemiologists. Clin. Infect. Dis. 40:1811-1817.[CrossRef][Medline]
    13. 13
  13. Kaczmarek, F. S., T. D. Gootz, F. Dib-Hajj, W. Shang, S. Hallowell, and M. Cronan. 2004. Genetic and molecular characterization of ß-lactamase-negative ampicillin-resistant Haemophilus influenzae with unusually high resistance to ampicillin. Antimicrob. Agents Chemother. 48:1630-1639.[Abstract/Free Full Text]
    14. 14
  14. Lomovskaya, O., M. S. Warren, A. Lee, J. Galazzo, R. Fronko, M. Lee, J. Blais, D. Cho, S. Chamberland, T. Renau, R. Leger, S. Hecker, W. Watkins, K. Hoshino, H. Ishida, and V. J. Lee. 2001. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 45:105-116.[Abstract/Free Full Text]
    15. 15
  15. Martínez-Martínez, L., I. García, S. Ballesta, V. J. Benedí, S. Hernández-Allés, and A. Pascual. 1998. Energy-dependent accumulation of fluorquinolones in quinolone-resistant Klebsiella pneumoniae strains. Antimicrob. Agents Chemother. 42:1850-1852.[Abstract/Free Full Text]
    16. 16
  16. Martínez-Martínez, L., A. Pascual, M. C. Conejo, I. García, P. Joyanes, A. Doménech-Sánchez, and V. J. Benedí. 2002. Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum ß-lactamase production. Antimicrob. Agents Chemother. 46:3926-3932.[Abstract/Free Full Text]
    17. 17
  17. Nazir, J., C. Urban, N. Mariano, J. Burns, B. Tommasulo, C. Rosenberg, S. Segal-Maurer, and J. J. Rahal. 2004. Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology Clin. Infect. Dis. 38:1564-1569.
    18. 18
  18. Reference deleted.
    19. 19
  19. Pérez-Vázquez, M., F. Román, M. C. Varela, R. Cantón, and J. Campos. 2003. Activities of thirteen quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance. J. Antimicrob. Chemother. 51:147-151.[Abstract/Free Full Text]
    20. 20
  20. Pérez-Vázquez, M., F. Román, B. Aracil, R. Cantón, and J. Campos. 2003. In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities. Antimicrob. Agents Chemother. 47:3539-3541.[Abstract/Free Full Text]
    21. 21
  21. Pérez-Vázquez, M., F. Román, B. Aracil, R. Cantón, and J. Campos. 2004. Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations. J. Clin. Microbiol. 42:1185.[Abstract/Free Full Text]
    22. 22
  22. Román, F., R. Cantón, M. Pérez-Vázquez, F. Baquero, and J. Campos. 2004. Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains. J. Clin. Microbiol. 42:1450-1459.[Abstract/Free Full Text]
    23. 23
  23. Trong, H. N., A.-L. Prunier, and R. Leclercq. 2005. Hypermutable and fluoroquinolone-resistant clinical isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 49:2098-2101.[Abstract/Free Full Text]
    24. 24
  24. Watson, M. E., Jr., J. L. Burns, and A. L. Smith. 2004. Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum. Microbiology 150:2947-2958.[Abstract/Free Full Text]
    25. 25
  25. Yoshida, H., M. Bogaki, M. Nakamura, and S. Nakamura. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34:1271-1272.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, April 2007, p. 1566-1569, Vol. 51, No. 4
0066-4804/07/$08.00+0     doi:10.1128/AAC.01437-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Hirakata, Y., Ohmori, K., Mikuriya, M., Saika, T., Matsuzaki, K., Hasegawa, M., Hatta, M., Yamamoto, N., Kunishima, H., Yano, H., Kitagawa, M., Arai, K., Kawakami, K., Kobayashi, I., Jones, R. N., Kohno, S., Yamaguchi, K., Kaku, M. (2009). Antimicrobial Activities of Piperacillin-Tazobactam against Haemophilus influenzae Isolates, Including {beta}-Lactamase-Negative Ampicillin-Resistant and {beta}-Lactamase-Positive Amoxicillin- Clavulanate-Resistant Isolates, and Mutations in Their Quinolone Resistance-Determining Regions. Antimicrob. Agents Chemother. 53: 4225-4230 [Abstract] [Full Text]  
  • Nakamura, S., Yanagihara, K., Morinaga, Y., Izumikawa, K., Seki, M., Kakeya, H., Yamamoto, Y., Kamihira, S., Kohno, S. (2009). Melting Curve Analysis for Rapid Detection of Topoisomerase Gene Mutations in Haemophilus influenzae. J. Clin. Microbiol. 47: 781-784 [Abstract] [Full Text]  
  • Yokota, S.-i., Ohkoshi, Y., Sato, K., Fujii, N. (2008). Emergence of Fluoroquinolone-Resistant Haemophilus influenzae Strains among Elderly Patients but Not among Children. J. Clin. Microbiol. 46: 361-365 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pérez-Vázquez, M.
Right arrow Articles by Campos, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pérez-Vázquez, M.
Right arrow Articles by Campos, J.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»